HURA · XBRL financial data
TuHURA Biosciences financial statements, every fiscal year
The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (HURA's year ends in late December)
| In millions of dollars | Jun 30, 2021 | Jun 30, 2022 | Jun 30, 2023 | †Jun 30, 2024 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | 0 | 0 |
| Research and development | 12 | 15 | 9 | 3 | 13 | 21 |
| General and administrative | 10 | 8 | 5 | 6 | 4 | 8 |
| Total operating expenses | (38) | 23 | 15 | 8 | 18 | 32 |
| Other operating income (expense) | (0) | 0 | 0 | 0 | — | — |
| Interest expense | 0 | — | — | — | 4 | 1 |
| Other income (expense) | — | — | — | — | (4) | 2 |
| Income tax expense (benefit) | — | — | — | — | 0 | 0 |
| Net income (loss) | (38) | (23) | (15) | (8) | (22) | (30) |
| Earnings per share, basic‡ USD per share | (80.00) | (26.00) | (9.27) | (0.32) | (1.21) | (0.63) |
| Earnings per share, diluted USD per share | — | — | — | — | (1.21) | (0.63) |
| Weighted average shares, basic‡ millions of shares | 1 | 1 | 2 | 26 | 19 | 48 |
| Weighted average shares, diluted millions of shares | — | — | — | — | 19 | 48 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-50 stock split (November 2022); filings made before it reported them unadjusted.
- † Share count changed about 31871x in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/1274 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (HURA's year ends in late December)
| In millions of dollars | Jun 30, 2021 | Jun 30, 2022 | Jun 30, 2023 | †Jun 30, 2024 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 11 | 12 | 2 | 5 | 13 | 4 |
| Total current assets | 12 | 13 | 3 | 6 | 20 | 5 |
| Property and equipment, net | 0 | 0 | 1 | 1 | 0 | 0 |
| Right-of-use asset | — | — | — | — | 0 | 0 |
| Goodwill | — | — | — | — | — | 11 |
| Total assets | 14 | 16 | 4 | 6 | 20 | 27 |
| Accounts payable | — | — | — | 1 | 3 | 4 |
| Accrued liabilities | — | — | — | 1 | 1 | 2 |
| Total current liabilities | 3 | 4 | 3 | 2 | 5 | 6 |
| Lease liability, non-current | — | — | — | — | 0 | 0 |
| Total liabilities | 3 | 4 | 3 | 2 | 5 | 6 |
| Accumulated deficit | (111) | (136) | (151) | (160) | (111) | (141) |
| Total stockholders' equity | 11 | 12 | 1 | 4 | 15 | 21 |
| Total liabilities and equity | 14 | 16 | 4 | 6 | 20 | 27 |
| Common shares outstanding (cover page)‡ millions of shares | 1 | 2 | 2 | 55,661 | 44 | 64 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-50 stock split (November 2022); filings made before it reported them unadjusted.
- † Share count changed about 31871x in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/1274 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (HURA's year ends in late December)
| In millions of dollars | Jun 30, 2021 | Jun 30, 2022 | Jun 30, 2023 | †Jun 30, 2024 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (38) | (23) | (15) | (8) | (22) | (30) |
| Stock-based compensation | — | — | — | — | 2 | 6 |
| Depreciation and amortization | — | — | — | — | 0 | 0 |
| Net cash from operating activities | (19) | (20) | (12) | (7) | (15) | (28) |
| Purchases of property and equipment | — | 0 | — | — | 0 | 0 |
| Net cash from investing activities | 1 | — | (0) | (0) | (6) | (1) |
| Proceeds from issuing common stock | — | — | — | — | 5 | 18 |
| Net cash from financing activities | 26 | 22 | 2 | 11 | 30 | 20 |
| Net change in cash | 8 | 1 | (10) | 3 | 9 | (9) |
- † Share count changed about 31871x in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/1274 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| TuHURA Biosciences | 1 | not reported | (8.6)* | 63.7M | 0.1 quarters | 10-QJun 30, 2026 |
| Enanta Pharmaceuticals | 33 | 14 | (10)* | 29.1M | 19.0 quarters | 10-QJun 30, 2026 |
| Protara Therapeutics | 17 | not reported | (15)* | 59.1M | 9.3 quarters | 10-QJun 30, 2026 |
| Caribou Biosciences | 26 | 1.5 | (23)* | 107.2M | 4.9 quarters | 10-QJun 30, 2026 |
| Fate Therapeutics | 32 | 2.1 | (23) | 119.8M | 6.6 quarters | 10-QJun 30, 2026 |
| Galectin Therapeutics | 13 | not reported | (2.4)* | 100.8M | 5.4 quarters | 10-QJun 30, 2026 |
| Protalix BioTherapeutics | 27 | 20 | (10)* | 80.6M | 2.6 quarters | 10-QJun 30, 2026 |
| Cartesian Therapeutics | 148 | 0 | (21)* | 30.3M | 7.0 quarters | 10-QJun 30, 2026 |
| Atossa Therapeutics | 26 | not reported | (9.6)* | 10.0M | 2.7 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.